hMC1R agonist 1



Cat. No.:	HY-P99004
CAS No.:	3028881-87-7
Molecular Formula:	$C_{54}H_{70}N_{14}O_8S_2$
Molecular Weight:	1107.35
Sequence:	metaXylene Ac-{Nle}-Cys-His-{d-Phe}-Arg-Trp-Cys-NH2
Sequence Shortening:	metaXylene Ac-{Nle}-CH-{d-Phe}-RWC-NH2
Target:	Melanocortin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (90.31 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9031 mL	4.5153 mL	9.0306 mL
	5 mM	0.1806 mL	0.9031 mL	1.8061 mL
	10 mM	0.0903 mL	0.4515 mL	0.9031 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	(EC_{50}=3 nM). hMC1R agonist 1 shows at least 300-fold selectivity for hMC1R over hMC3R (b>EC_{50}=902 nM), hMC4R (b>EC_{50} =915 nM), and hMC5R (b>EC_{50}=>1000 nM). hMC1R agonist 1 has the potential for the therapeutic intervention of melanocortin family[1].
IC_{50} & Target	MC1R

REFERENCES

[1]. Nafie MS, et al. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorg Chem. 2022; 122:105708.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA